Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
Stopped early · Phase 1
Conditions studied: Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
In brief
RATIONALE: Drugs such as temsirolimus and valproic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Valproic acid may also stop the growth of solid tumors by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and the best dose of temsirolimus when given together with valproic acid in treating young patients with relapsed neuroblastoma, bone sarcoma, or soft tissue sarcoma.
Key facts
- Study ID
- NCT01204450
- Run by
- UNC Lineberger Comprehensive Cancer Center
- People needed
- 7
- Starts
- 2009-11-01
- Expected to finish
- 2013-03-01
- Last updated by the study team
- 2016-12-23
Who can join
Age: 2 and older, up to 18. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill — Chapel Hill, North Carolina, United States
- Carolina Healthcare System — Charlotte, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.